12 results
This study aims to evaluate the safety, tolerability and sedative proporties of a single dose of intransally administered dexmedetomidine in person odler than 65 years, differentiating between person using beta-blocking medication and those not…
To demonstrate non-inferiority of conscious sedation with intranasal dexmedetomidine for performing dental care in patients with intellectual disability and dentophobia.
The purpose of this study is to observe the usability of Dexmedetomidine and to determine the overall satisfaction of the patient.
The aim of this study is to determine the patients* and endoscopists experiences and patients* safety with different sedation protocols.
Primary objective:The study has hierarchical co-primary objectives to demonstrate that:- Firstly: dexmedetomidine is at least as effective as sedation with propofol and daily sedation stops, in maintaining a target depth of sedation in ventilated…
Primary objective:the effects of sedation with clonidine or dexmedetomidine on the duration of haloperidol-resistent delirium in intensive care patientsSecondary objectives:the effect of treatment with clonidine or dexmedetomidine on1. total of…
The purpose of this study is to observe the usability of dexmedetomidine compared to the standard therapy (propofol) and to determine the overall satisfaction of the patient.
Elinzanetant is an investigational compound. It is not approved for sale. That means it can only be used in studies like this one. Elinzanetant has been extensively tested in the laboratory. It has also been already administered to approximately 300…
Primary Safety Objective: To describe the safety profile of 20vPnC
Main objective: 1. Is there a 24hr-postoperative difference in immunological response between conventional and immune protective anesthesia?Secondary objectives:Is there a difference between patients with conventional and immune protective…
The objective of this trial is to collect additional safety data.The further objective of this trial is to collect long-term efficacy measures as well as to assess the treatment effect on:- disability and productivity- functional impairment- health-…
The primary objective of this trial in CIAS is to assess the efficacy in improving cognitive impairment using MCCB in patients with schizophrenia treated for 26 weeks with Iclepertin 10mg as compared with placebo.